Established Thought Leader in the CAR-T Field
Dr. Morgan joins the company from
“We are excited that Richard is joining bluebird bio,” stated
Dr. Morgan was a member of the team that preformed the world’s first
human gene therapy experiments in 1990 and in 2006 he was the first to
report that genetically engineered T cells can cause cancer regression
in humans. In his 30 years career, Dr. Morgan has received multiple
awards, most recently the Technology Transfer Award from the
“This is a revolutionary time in the fields of immunotherapy and gene therapy,” stated Dr. Morgan. “bluebird bio has established a leading group of researchers in the field of CAR-T, a novel approach to treating cancers and potentially, a wide range of immune mediated diseases. I look forward to working with the team to advance these treatments towards the clinic.”
About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing
potentially transformative gene therapies for severe genetic and orphan
diseases. bluebird bio has two clinical-stage programs in development.
The most advanced product candidate, Lenti-D, recently initiated a phase
2/3 study for the treatment of childhood cerebral adrenoleukodystrophy
(CCALD), a rare, hereditary neurological disorder affecting young boys.
The next most advanced product candidate, LentiGlobin, is currently in a
phase 1/2 study in
bluebird bio also has an early-stage chimeric antigen receptor-modified
T cell (CAR-T) program for oncology in partnership with
bluebird bio has operations in
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the advancement of our clinical trials. Any
forward-looking statements in this press release are based on
management's current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties
include, but are not limited to, the risk of cessation or delay of any
of the ongoing or planned clinical trials and/or our development of our
product candidates, the risk that the results of previously conducted
studies involving similar product candidates will not be repeated or
observed in ongoing or future studies involving current product
candidates, the risk that our collaboration with
Source: bluebird bio, Inc.
bluebird bio, Inc.
Richard E. T. Smith, Ph.D., 617-588-3321
Pure Communications, Inc.
Dan Budwick, 973-271-6085